Aurobindo Pharma Fixes Record Date on April 12, 2026 for ₹800 Crore Share Buyback

Aurobindo Pharma has set April 12, 2026, as the record date for its upcoming share buyback. Shareholders who hold the stock on this date will be eligible to participate in the buyback offer.

Buyback Details

The company plans to buy back shares through the tender offer route:

• Buyback size: ₹800 crore
• Shares to be repurchased: Up to 54.24 lakh shares
• Buyback price: ₹1,475 per share
• Participation: Open to all eligible shareholders, including promoters
• Shares will be bought back on a proportionate basis

Impact on Capital and Reserves

The buyback represents:

• 3.93% of the company’s paid-up equity capital and free reserves (standalone)
• 2.62% of the same on a consolidated basis

About Aurobindo Pharma

Aurobindo Pharma is an Indian multinational pharmaceutical company headquartered in HITEC City, Hyderabad, with its U.S. headquarters in East Windsor, New Jersey. The company produces generic medicines and active pharmaceutical ingredients (APIs).

Read More: Paytm Share Price Gains Over 2%; Introduces Biometric UPI Payments and Cardless ATM Withdrawals Amid RBI Guidelines!

Aurobindo Pharma Share Price Movement

Aurobindo Pharma share price (NSE: AUROPHARMA) was trading at ₹1,353.70 on April 7, up 0.99% for the day. The stock opened at ₹1,345 and moved between a low of ₹1,332.70 and a high of ₹1,354.50 during the session. Over the past year, the stock has touched a 52-week high of ₹1,359.90 and a low of ₹1,010. It offers a dividend yield of 0.30%, with a quarterly dividend amount of ₹1.02.

Conclusion

The buyback gives eligible shareholders an opportunity to tender shares at a fixed premium price. Investors must hold the stock on April 12 to participate in the offer.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.